Pharmacist Ethics | Patient Safety Podcast 1 credit hour

Access to medications for opioid use disorder (MOUD) remains a critical component of addressing the ongoing opioid crisis, and recent federal authorization now allows pharmacists to independently prescribe buprenorphine following appropriate training. This course reviews the regulatory changes, outlines clinical and operational considerations for pharmacist-led MOUD prescribing, and discusses the opportunities and responsibilities that accompany expanded prescriptive authority. You will gain practical insight into how integrating MOUD prescribing into pharmacy practice can improve treatment access while maintaining safe, evidence-based care.

Available in Subscription

This course is included in the following subscription:

Pharmacist CE Subscription

Pharmacist CE Subscription

Renewed Annually
$99.00 / year

Learning Objectives

Upon successful completion of this course, pharmacists should be able to:
1. Describe recent federal policy changes authorizing pharmacists to independently prescribe buprenorphine for opioid use disorder.
2. Identify clinical, regulatory, and workflow considerations associated with integrating MOUD prescribing into pharmacy practice.

Faculty

Rachel Maynard, PharmD

Disclosures:

Rachel Maynard has no relevant financial relationships with ineligible companies to disclose.

Korey Kreider, PharmD

Disclosures:

Korey Kreider has no relevant financial relationships with ineligible companies to disclose.

Course Details